Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide

References

• Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types. and proposal of taxonomic amendments. Virology 2010;401(1):70-9
   PubMed Web of Science ®Google Scholar
• Chouhy D, Gorosito M, Sanchez A, et al. New generic primer system targeting mucosal/genital and cutaneous human papillomaviruses leads to the characterization of HPV115, a novel Beta-papilloma virus species 3. Virology 2010;397(1):205-16
   Google Scholar
• Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002;89(2):229-40
   PubMed Web of Science ®Google Scholar
• Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol (Berl) 2004;193(1):35-44
   PubMed Web of Science ®Google Scholar
• Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191(5):731-8
   PubMed Web of Science ®Google Scholar
• Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;1:4:8
   Google Scholar
• Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88(1):63-73
   PubMed Web of Science ®Google Scholar
• Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999;37(10):3316-22
   PubMed Web of Science ®Google Scholar
• Ball SL, Winder DM, Vaughan K, et al. Analyses of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol 2011;83(8):1345-50
   Google Scholar
• Clifford GM, Gallius S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366(9490):991-8
   PubMed Web of Science ®Google Scholar
• Petry KU, Luyten A, Justus A, et al. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84—results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2012;12:367
   PubMed Web of Science ®Google Scholar
• Palefsky JM. Human Papillomavirus-Related Disease in Men: not Just a Women’s Issue. J Adolesc Health 2010;46(4 Suppl):S12-19
   PubMed Web of Science ®Google Scholar
• Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26(Suppl 10):K17-28
   PubMed Web of Science ®Google Scholar
• Arima Y, Winer RL, Feng Q, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis 2010;202(8):1181-4
   Google Scholar
• Szeimies RM, Landthaler M. Photodynamic therapy and fluorescence diagnosis of skin cancers. Recent Results Cancer Res 2002;160:240-5
   Google Scholar
• Lin C, Lau JT, Ho KM, et al. Incidence of genital warts among the Hong Kong general adult population. BMC Infect Dis 2010;10:272
   Google Scholar
• Kjær SK, Nam TT, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2010;196(10):1447-54
   Google Scholar
• De Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7(7):453-9
   PubMed Web of Science ®Google Scholar
• Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004;31(12):748-52
   PubMed Web of Science ®Google Scholar
• Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006;368(9548):1706-28
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012;European Guideline for the Management of Anogenital Warts. J Eur Acad Dermatol Venereol 2012;27(3):e263-70
   Google Scholar
• Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84(3):161-6
   Google Scholar
• Brodell LA, Mercurio MG, Brodell RT. The diagnosis and treatment of human papillomavirus-mediated genital lesions. Cutis 2007;79(4 Suppl):5-10
   Google Scholar
• Kodner CM, Nasraty S. Management of genital warts. Am Fam Physician 2004;70(12):2335-42
   PubMed Web of Science ®Google Scholar
• Veldhuijzen NJ, Snijders PJ, Reiss P. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010;10(12):862-74
   PubMed Web of Science ®Google Scholar
• Rosa MI, Fachel JM, Rosa DD, et al. Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol 2008;199(6):617
   Google Scholar
• Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008;198(7):971-8
   PubMed Web of Science ®Google Scholar
• Hamouda T, Freij MA, Saleh M. Management of genital warts in pregnancy. Clin Exp Obstet Gynecol 2012;39(2):242-4
   Google Scholar
• Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84(3):161-6
   Google Scholar
• Kacerovska D, Pizinger K, Kumpova M, Cetkovska P. Genital warts treated by photodynamic therapy. Skinmed 2007;6(6):295-7
   Google Scholar
• George J, Welton ML. Human papillomavirus, condylomata acuminata, and anal neoplasia. Clinics Colon Rectal Surg 2004;17(4):220-30
   Google Scholar
• Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990;12(suppl 6):S620-32
   PubMedGoogle Scholar
• Baggish MS. Carbon dioxide laser treatment for condylomata acuminata venereal infections. Obstet Gynecol 1980;55(6):711-15
   Google Scholar
• Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol 1991;248(7):425-7
   PubMed Web of Science ®Google Scholar
• Blokker RS, Lock TM, de Boorder T. Comparing thulium laser and Nd: YAG laser in the treatment of genital and urethral condylomata acuminata in male patients. Lasers Surg Med 2013;45(9):582-8
   Google Scholar
• Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990;12(suppl 6):S620-32
   PubMedGoogle Scholar
• Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;6(1-2):143-8
   PubMed Web of Science ®Google Scholar
• Nucci V, Torchia D, Cappugi P. Treatment of anogenital condylomata acuminata with topical photodynamic therapy: report of 14 cases and review. Int J Infect Dis 2010;14(Suppl 3):e280-2
   Google Scholar
• Ayala F, Grimaldi E, Perfetto B, et al. 5-Aminolaevulinic acid and photodynamic therapy reduce HSV-1 replication in HaCat cells through an apoptosis-independent mechanism. Photodermatol Photoimmunol Photomed 2008;24(5):237-43
   Google Scholar
• Rossi R, Bruscino N, Ricceri F, et al. Photodynamic treatment for viral infections of the skin. G Ital Dermatol Venereol 2009;144(1):79-83
   Google Scholar
• North J, Neyndorff H, King D, Levy JG. Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative. Blood Cells 1992;18(1):129-39
   Google Scholar
• Forster B, Klein A, Szeimies RM, Maisch T. Penetration enhancement of two topical 5-aminolaevulinic acid formulations for photodynamic therapy by erbium: YAG laser ablation of the stratum corneum: continuous versus fractional ablation. Exp Dermatol 2010;19(9):806-12
   PubMed Web of Science ®Google Scholar
• Juzeniene A, Juzenas P, Moan J. Application of 5-aminolev-ulinic acid and its derivatives for photodynamic therapy in vitro and in vivo. Methods Mol Biol 2010;635:97-106
   PubMedGoogle Scholar
• Wolf R, Davidovici B. Treatment of genital warts: facts and controversies. Clin Dermatol 2010;28(5):546-8
   Google Scholar
• Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12(3):5
   PubMedGoogle Scholar
• Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35(Suppl 2):S210-24
   PubMedGoogle Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-53
   PubMed Web of Science ®Google Scholar
• Spear GT, Hart M, Olinger GG, et al. The role of the complement system in virus infections. Curr Top Microbiol Immunol 2001;260:229-45
   Google Scholar
• Platanias LC. Mechanisms of type-I and type-II interferon-mediated signalling. Nat Rev Immunol 2005;5(5):375-86
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008;9(5):503-10
   PubMed Web of Science ®Google Scholar
• Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 2010;22(2):223-30
   PubMed Web of Science ®Google Scholar
• Skinner RB Jr. Imiquimod. Dermatol Clin 2003;21(2):291-300
   Google Scholar
• Friedman OM, Klass DL, Seligman AM. Preparation of N-phosphorylated derivatives of bis-P-chloroethylamine. J Amer Chem Soc 1954;76(3):655-8
   Google Scholar
• Arnold H, Bourseaux F, Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. Nature 1958;181:931
   PubMed Web of Science ®Google Scholar
• Tosi P, Zamagni E, Ronconi S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000;14(7):1310-13
   Google Scholar
• Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol 2004;32(5):435-40
   PubMedGoogle Scholar
• Dong Q, Barsky D, Colvin ME, et al. A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5’-d(GAC). Proc Natl Acad Sci USA 1995;92(26):12170-4
   Google Scholar
• Roos WP, Kaina BW. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12(9):440-50
   PubMed Web of Science ®Google Scholar
• Rooney PH, Telfer C, McFadyen MC, et al. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets 2004;4(3):257-65
   Google Scholar
• Russo JE, Hilton J, Colvin OM. The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide. Prog Clin Biol Res 1989;290:65-79
   Google Scholar
• Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988;61(3):451-7
   PubMed Web of Science ®Google Scholar
• Haselberger MB, Schwinghammer TL. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995;29(9):918-21
   PubMed Web of Science ®Google Scholar
• Jones RJ, Barber JP, Vala MS. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85(10):2742-6
   PubMed Web of Science ®Google Scholar
• Sladek EN. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat Res 2002;112:161-75
   PubMedGoogle Scholar
• Tanner B, Hengstler JG, Dietrich B, et al. Glutathione, dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 1997;65(1):54-62
   PubMedGoogle Scholar
• Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997;89(1):243-55
   Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14(3):925-34
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328(14):1002-6
   PubMed Web of Science ®Google Scholar
• Gordon MY, Goldman JM, Gordon-Smith EC. 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 1985;9(8):1017-21
   Google Scholar
• Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet 1972;1(7745):284-9
   PubMed Web of Science ®Google Scholar
• Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344(3):175-81
   PubMed Web of Science ®Google Scholar
• Makhani NM, Branson HM, Stazzone L, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009;72(24):2076-82
   PubMed Web of Science ®Google Scholar
• Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 1975;141(3):697-702
   PubMedGoogle Scholar
• Röllinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 1977;145(2):455-9
   Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151-64
   PubMed Web of Science ®Google Scholar
• Weiss L, Donkova-Petrini V, Caccavelli L, et al. Human immunodeficiency virus-driven expansion of CD4+ CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004;104(10):3249-56
   Google Scholar
• Cabrera R, Tu Z, Xu Y, et al. An immunomodulatory role for CD4+ CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004;40(5):1062-71
   Google Scholar
• Amante FH, Stanley AC, Randall LM, et al. A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol 2007;171(2):548-59
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4+ 25+T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862-8
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-8
   PubMed Web of Science ®Google Scholar
• Young SD, Whissell M, Noble JC, et al. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006;12(10):3092-8
   PubMed Web of Science ®Google Scholar
• Stanley M. HPV—a master at avoiding the host’s defences. HPV Today 2007;11:1-16
   Google Scholar
• Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002;169(6):3242-9
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24(suppl):S16-22
   Google Scholar
• Guess JC, McCance DJ. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 2005;79(23):14852-62
   Google Scholar
• Cao Y, Zhao J, Lei Z, et al. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata. J Immunol 2008;180(11):7681-6
   Google Scholar
• Cao Y, Zhao J, Yang Z, et al. CD4+ FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol 2010;136(1):21-9
   Google Scholar
• ClinicalTrials.gov number NCT00999986. Available from: clinicaltrials.gov/ct2/show/NCT00999986
   Google Scholar
• Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+ CD25+ FOXP3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010;70(12):4850-8
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J. Lei Z, et al. miR-142-3p restricts cAMP production in CD4+ CD25- T cells and CD4+ CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009;10(2):180-5
   PubMed Web of Science ®Google Scholar
• Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007;204(6):1303-131
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204(6):1257-65
   PubMed Web of Science ®Google Scholar